Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
这项随机、双盲、多中心 II 期试验表明,新型纳米缓释制剂 STS01(1% 浓度)在治疗轻中度斑片状斑秃方面显著优于安慰剂,具有明确的剂量反应关系且安全性可控,为后续 III 期研究奠定了基础。